145 related articles for article (PubMed ID: 15171451)
1. [Renal protective action of T-, L-, and N-type Ca channel blockers].
Hayashi K
Nihon Rinsho; 2004 Mar; 62 Suppl 3():654-61. PubMed ID: 15171451
[No Abstract] [Full Text] [Related]
2. Ca2+ channel subtypes and pharmacology in the kidney.
Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
[TBL] [Abstract][Full Text] [Related]
3. Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats.
Baylis C; Qiu C; Engels K
Am J Kidney Dis; 2001 Dec; 38(6):1292-7. PubMed ID: 11728963
[TBL] [Abstract][Full Text] [Related]
4. [Molecular effects of new calcium antagonists: is the principle of parcimony out of place?].
Richard S; Virsolvy A; Fort A
Ann Cardiol Angeiol (Paris); 2008 Jun; 57(3):166-73. PubMed ID: 18565491
[TBL] [Abstract][Full Text] [Related]
5. [Calcium antagonists: current and future applications based on new evidence. Renal protective action of calcium channel blockers].
Kimura G
Clin Calcium; 2010 Jan; 20(1):94-9. PubMed ID: 20048440
[TBL] [Abstract][Full Text] [Related]
6. [New calcium channel blockers for the treatment of hypertension].
Tamargo J
Hipertens Riesgo Vasc; 2017; 34 Suppl 2():5-8. PubMed ID: 29908667
[TBL] [Abstract][Full Text] [Related]
7. Scaffold-based design and synthesis of potent N-type calcium channel blockers.
Zamponi GW; Feng ZP; Zhang L; Pajouhesh H; Ding Y; Belardetti F; Pajouhesh H; Dolphin D; Mitscher LA; Snutch TP
Bioorg Med Chem Lett; 2009 Nov; 19(22):6467-72. PubMed ID: 19815411
[TBL] [Abstract][Full Text] [Related]
8. Functional and pharmacological consequences of the distribution of voltage-gated calcium channels in the renal blood vessels.
Hansen PB
Acta Physiol (Oxf); 2013 Apr; 207(4):690-9. PubMed ID: 23351056
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers.
Rhim H; Lee YS; Park SJ; Chung BY; Lee JY
Bioorg Med Chem Lett; 2005 Jan; 15(2):283-6. PubMed ID: 15603940
[TBL] [Abstract][Full Text] [Related]
10. L-/N-type calcium channel blockers and proteinuria.
Ando K
Curr Hypertens Rev; 2013 Aug; 9(3):210-8. PubMed ID: 24479751
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.
Masuda T; Ogura MN; Moriya T; Takahira N; Matsumoto T; Kutsuna T; Hara M; Aiba N; Noda C; Izumi T
Cardiovasc Ther; 2011 Feb; 29(1):46-53. PubMed ID: 20337636
[TBL] [Abstract][Full Text] [Related]
12. Low-threshold L-type calcium channels in rat dopamine neurons.
Durante P; Cardenas CG; Whittaker JA; Kitai ST; Scroggs RS
J Neurophysiol; 2004 Mar; 91(3):1450-4. PubMed ID: 14645383
[TBL] [Abstract][Full Text] [Related]
13. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H
Hypertens Res; 2007 Jul; 30(7):621-6. PubMed ID: 17785930
[TBL] [Abstract][Full Text] [Related]
14. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and SAR studies of a novel series of T-type calcium channel blockers.
Park SJ; Park SJ; Lee MJ; Rhim H; Kim Y; Lee JH; Chung BY; Lee JY
Bioorg Med Chem; 2006 May; 14(10):3502-11. PubMed ID: 16434203
[TBL] [Abstract][Full Text] [Related]
16. Acetylcholine release at neuromuscular junctions of adult tottering mice is controlled by N-(cav2.2) and R-type (cav2.3) but not L-type (cav1.2) Ca2+ channels.
Pardo NE; Hajela RK; Atchison WD
J Pharmacol Exp Ther; 2006 Dec; 319(3):1009-20. PubMed ID: 16982704
[TBL] [Abstract][Full Text] [Related]
17. T-type Ca channel blockers in patients with chronic kidney disease in clinical practice.
Abe M; Okada K; Soma M
Curr Hypertens Rev; 2013 Aug; 9(3):202-9. PubMed ID: 24479749
[TBL] [Abstract][Full Text] [Related]
18. State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel.
Freeze BS; McNulty MM; Hanck DA
Mol Pharmacol; 2006 Aug; 70(2):718-26. PubMed ID: 16699084
[TBL] [Abstract][Full Text] [Related]
19. Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.
Moore KH; Clemmer JS
Am J Physiol Renal Physiol; 2021 Oct; 321(4):F548-F557. PubMed ID: 34486399
[TBL] [Abstract][Full Text] [Related]
20. Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers.
Ku IW; Cho S; Doddareddy MR; Jang MS; Keum G; Lee JH; Chung BY; Kim Y; Rhim H; Kang SB
Bioorg Med Chem Lett; 2006 Oct; 16(19):5244-8. PubMed ID: 16876404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
